文献速递肝病消化道肿瘤与早癌

PKCα/ZFP64/CSF1轴重塑肿瘤微环境并驱动肝细胞癌抗PD1耐药

PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2022-02-24

研究通过下一代测序、多重免疫荧光等方法发现,ZFP64在抗PD1耐药肝细胞癌患者肿瘤组织中频繁上调。ZFP64通过促使巨噬细胞向M2表型极化并形成抑制性肿瘤微环境驱动抗PD1耐药。机制上PKCα磷酸化ZFP64 S226位点促进其核转位并转录激活CSF1,Gö6976或仑伐替尼阻断该轴可恢复抗PD1敏感性。

要点

  • ZFP64在抗PD1耐药肝细胞癌患者肿瘤组织中频繁上调,驱动巨噬细胞向M2表型极化。
  • PKCα直接磷酸化ZFP64的S226位点,促进其核转位并转录激活CSF1。
  • Gö6976或仑伐替尼阻断PKCα/ZFP64/CSF1轴可重塑肿瘤微环境并恢复抗PD1敏感性。

核心结论

  • PKCα/ZFP64/CSF1轴对触发免疫逃逸和抗PD1耐受至关重要,用Gö6976或仑伐替尼抑制该轴可克服肝细胞癌的抗PD1耐药。

研究设计与样本

  • 研究采用下一代测序、多重免疫荧光和双色免疫组织化学,并构建原位肝细胞癌异种移植肿瘤模型以识别与抗PD1耐受相关的关键基因。
  • 采用自发成瘤转基因小鼠模型、体外共培养系统、质谱流式细胞术和多重免疫荧光探究ZFP64对肿瘤进展和免疫逃逸的生物学功能。
  • 采用RNA测序、染色质免疫沉淀测序和质谱等分子与生化策略探究ZFP64的潜在机制。

主要发现

  • ZFP64在抗PD1耐药肝细胞癌患者肿瘤组织中频繁上调。
  • 升高的ZFP64通过促使巨噬细胞向替代激活表型(M2)极化并形成抑制性肿瘤微环境驱动抗PD1耐药。
  • PKCα直接磷酸化ZFP64的S226位点,导致其核转位并转录激活巨噬细胞集落刺激因子(CSF1)。
  • 肝细胞癌来源的CSF1将巨噬细胞转化为M2表型以驱动免疫逃逸和抗PD1耐受。

关键数值与推荐

  • Gö6976(一种蛋白激酶抑制剂)和仑伐替尼(一种多激酶抑制剂)通过阻断PKCα/ZFP64/CSF1轴重塑肿瘤微环境并恢复对抗PD1的敏感性。

临床怎么用

  • 作者提出PKCα/ZFP64/CSF1轴是触发免疫逃逸和抗PD1耐受的关键,用Gö6976或仑伐替尼抑制该轴可克服肝细胞癌的抗PD1耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Despite remarkable advances in treatment, most patients with hepatocellular carcinoma (HCC) respond poorly to anti-programmed cell death 1 (anti-PD1) therapy. A deeper insight into the tolerance mechanism of HCC against this therapy is urgently needed. METHODS: We performed next-generation sequencing, multiplex immunofluorescence, and dual-color immunohistochemistry and constructed an orthotopic HCC xenograft tumor model to identify the key gene associated with anti-PD1 tolerance. A spontaneously tumorigenic transgenic mouse model, an in vitro coculture system, mass cytometry, and multiplex immunofluorescence were used to explore the biological function of zinc finger protein 64 (ZFP64) on tumor progression and immune escape. Molecular and biochemical strategies like RNA-sequencing, chromatin immunoprecipitation-sequencing and mass spectrometry were used to gain insight into the underlying mechanisms of ZFP64. RESULTS: We showed that ZFP64 is frequently upregulated in tumor tissues from patients with anti-PD1-resistant HCC. Elevated ZFP64 drives anti-PD1 resistance by shifting macrophage polarization toward an alternative activation phenotype (M2) and fostering an inhibitory tumor microenvironment. Mechanistically, we primarily demonstrated that protein kinase C alpha (PKCα) directly phosphorylates ZFP64 at S226, leading to its nuclear translocation and the transcriptional activation of macrophage colony-stimulating factor (CSF1). HCC-derived CSF1 transforms macrophages to the M2 phenotype to drive immune escape and anti-PD1 tolerance. Notably, Gö6976, a protein kinase inhibitor, and lenvatinib, a multi-kinase inhibitor, reset the tumor microenvironment and restore sensitivity to anti-PD1 by blocking the PKCα/ZFP64/CSF1 axis. CONCLUSIONS: We propose that the PKCα/ZFP64/CSF1 axis is critical for triggering immune evasion and anti-PD1 tolerance. Inhibiting this axis with Gö6976 or lenvatinib overcomes anti-PD1 resistance in HCC. LAY SUMMARY: Despite remarkable treatment progress, most patients with hepatocellular carcinoma respond poorly to anti-PD1 therapy (a type of immunotherapy). A deeper insight into the tolerance mechanisms to this therapy is urgently needed. Herein, we unravel a previously unexplored mechanism linking tumor progression, macrophage polarization, and anti-PD1 resistance, and offer an attractive novel target for anti-PD1 combination therapy, which may benefit patients with hepatocellular carcinoma.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wei CY, Zhu MX, Zhang PF, et al. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol. 2022. PMID: 35219791. doi:10.1016/j.jhep.2022.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。